RXRX241206C9500
- 0.03
- -0.02-40.00%
Recursion Pharmaceuticals Newsroom
Recursion Pharmaceuticals Insider Sold Shares Worth $285,600, According to a Recent SEC Filing
Ulta Beauty Posts Upbeat Results, Joins Asana, Lululemon, Hewlett Packard Enterprise And Other Big Stocks Moving Higher On Friday
Jim Cramer on Recursion Pharmaceuticals, Inc. (RXRX): 'It Is Worthwhile Speculation'
10 Health Care Stocks Whale Activity In Today's Session
Recursion Pharmaceuticals CFO Ben Taylor to Join Exscientia
Recursion Pharmaceuticals (RXRX) Bold Acquisition Makes It a Leader in AI Drug Discovery
Recursion Announces First Patient Dosed In Phase 1/2 Clinical Study Of REC-1245, A RBM39 Degrader For Biomarker-Enriched Solid Tumors And Lymphoma
Express News | Recursion Announces First Patient Dosed in Phase 1/2 Clinical Study of REC-1245, a Potential First-in-Class, Rbm39 Degrader for Biomarker-Enriched Solid Tumors and Lymphoma
Nvidia Bought 6 Artificial Intelligence (AI) Stocks, but This 1 Has Soared the Most
XPeng, NovoCure, Merus, Gap And Other Big Stocks Moving Higher On Monday
Following nvidia to invest in ai? These three small cap ai stocks are worth attention.
As the current leader in AI technology, nvidia also participates in practical application scenarios of AI+ through investment and shareholding.
(RXRX) - Analyzing Recursion Pharmaceuticals's Short Interest
Jim Cramer: Reddit Is 'Fabulous,' Dow Is A 'Tough' One
Cathie Wood Sees $400B Opportunity In Biologics — How Have Her Bets Fared?
Analysts Offer Insights on Healthcare Companies: Vor Biopharma (VOR), Recursion Pharmaceuticals (RXRX) and AN2 Therapeutics, Inc. (ANTX)
BofA Securities Maintains Recursion Pharmaceuticals(RXRX.US) With Hold Rating, Cuts Target Price to $12
Hold Rating Recommended for Recursion Pharmaceuticals Post-Merger With Exscientia: Upside Potential Amidst Clinical Uncertainties
KeyBanc Maintains Recursion Pharmaceuticals(RXRX.US) With Buy Rating, Maintains Target Price $12
Recursion Pharmaceuticals Analyst Ratings
Strategic Mergers and Financial Strength: Recursion Pharmaceuticals' Path to Growth